LLY insider reports 301,342-share sale; 94.23M shares remain
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 301,342 shares ($260,165,031)
Net Sell
8 txns
Insider
LILLY ENDOWMENT INC
Role
10% Owner
Sold
301,342 shs ($260.17M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 197,814 | $862.631 | $170.64M |
| Sale | Common Stock | 54,191 | $863.424 | $46.79M |
| Sale | Common Stock | 15,671 | $864.528 | $13.55M |
| Sale | Common Stock | 10,356 | $865.596 | $8.96M |
| Sale | Common Stock | 10,358 | $866.547 | $8.98M |
| Sale | Common Stock | 4,602 | $867.544 | $3.99M |
| Sale | Common Stock | 5,440 | $868.442 | $4.72M |
| Sale | Common Stock | 2,910 | $869.466 | $2.53M |
Holdings After Transaction:
Common Stock — 94,335,506 shares (Direct)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.00 to $862.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $863.00 to $863.9999, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $864.00 to $864.9985, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $865.00 to $865.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $866.00 to $866.997, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $867.00 to $867.9983, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $868.00 to $868.9994, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $869.0023 to $869.9057, inclusive.
FAQ
What did LLY’s insider report on Form 4?
Open-market sales of common stock totaling 301,342 shares on 10/31/2025.
What was the transaction code used?
Code S for open-market sale transactions.
Were derivative securities reported in this filing?
No derivative securities are listed in the provided table.
Who signed the filing?
“/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”